Dostarlimab: First Approval

Dostarlimab (Jemperli (TM); GlaxoSmithKline) is a humanized monoclonal antibody programmed death-1 (PD-1) receptor antagonist being developed for the treatment of various cancers. Based on preliminary results from the GARNET trial dostarlimab has recently been approved in the EU and USA for the treatment of adult patients with mismatch repair deficient recurrent or advanced endometrial cancer. This article summarizes the milestones in the development of dostarlimab leading to these first approvals.

Automated summary

Dostarlimab, a humanized monoclonal antibody PD-1 receptor antagonist, has been approved for the treatment of various cancers in the EU and USA. This marks a significant milestone in the development of the drug.